Subscribe To
ANPCY / ANGLE hails the latest breast cancer study
ANPCY News
By Proactive Investors
October 25, 2023
ANGLE technolgy could help provide a more targeted approach to head and neck cancer
ANGLE plc, a leading company in liquid biopsy technology, has unveiled promising research findings that could help transform the treatment of head and more_horizontal
By Proactive Investors
October 3, 2023
ANGLE hails the latest breast cancer study
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy and cancer diagnostics specialist, has hailed a study that could change the way doctors monitor a more_horizontal
By Proactive Investors
September 29, 2023
ANGLE technology showcased in six poster presentations at cancer event
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a specialist in liquid biopsy and circulating tumour cell (CTC) diagnostics, said that nine posters featuring its gr more_horizontal
By Proactive Investors
September 7, 2023
ANGLE PLC: Making solid commercial progress
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a specialist in liquid biopsies for cancer detection, is showing early signs of progress despite industry headwinds. more_horizontal
By Proactive Investors
September 7, 2023
ANGLE makes encouraging start to year; momentum set to continue in H2
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy company specialising in circulating tumour cell (CTC) diagnostic solutions, anticipates continue more_horizontal
By Proactive Investors
September 4, 2023
ANGLE unveils groundbreaking cancer diagnostic tool
ANGLE plc, a frontrunner in liquid biopsy technology, has unveiled its latest innovation, the Portrait Flex CTC assay - a cutting-edge diagnostic tool more_horizontal
By Proactive Investors
June 5, 2023
ANGLE makes two key appointments to help deliver "strategic and commercial objectives"
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of the Parsortix liquid biopsy, has enhanced its executive roster with two key appointments: Brett Swa more_horizontal
By Proactive Investors
May 25, 2023
ANGLE technology to be used in cancer clinical trial
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a pioneer of liquid biopsy technology, announced a significant contract win with Artios Pharma. Under the deal ANG more_horizontal